IAP

MX107 is a survivin inhibitor which induces degradation of XIAP and/or cIAP1, and suppresses genotoxic NF-kappaB activation.

A 410099.1 is a BIRC (baculoviral IAP repeat-containing protein) inhibitor with EC50 values of 4.6, 9.2, 15.6, 19.9, and 93.9 nM for BIRC2/3/4/7/8.

CUDC-427 (GDC-0917) is an orally bioactive and pan antagonist of inhibitor of apoptosis proteins(IAPs). CUDC-427 can be used in research on cancers.

Anticancer agent 127 (142D6), an IAP inhibitor, covalently binds to the BIR3 domains of XIAP, cIAP1, and cIAP2, with IC50 values of 12 nM, 14 nM, and 9 nM,

Anticancer agent 128 (compound 1) is an IAP inhibitor that covalently binds to the BIR3 domains of XIAP, cIAP1, and cIAP2, exhibiting IC50 values of 24.9 nM, 19

XIAP antagonist 1 (compound A4) is a specific XIAP inhibitor that promotes the degradation of XIAP through the ubiquitin-proteasome pathway [1].

XIAP degrader-1 is a small primary amine molecule that promotes the degradation of X-linked apoptosis inhibitory protein (XIAP).

CSLP43 is a selective inhibitor of RIPK2 and XIAP, presenting an IC₅₀ of 19.9 nM for human RIPK2. It binds to the ATP binding pocket of RIPK2, disrupting interactions with the XIAPBIR2 or cIAP1BIR2 domains. CSLP43 effectively inhibits RIPK2 ubiquitination, NOD1- and NOD2-dependent inflammatory signaling pathways, as well as NF-κB activation associated with NOD agonists. It specifically targets NOD1/NOD2 signaling pathways without affecting the kinase activity of RIPK1 or RIPK3. CSLP43 is applicable in research related to Crohn's disease, Blau syndrome, early-onset sarcoidosis, and early-onset inflammatory bowel disease.

XB2M54 is a selective XIAP antagonist that inhibits NOD2-mediated inflammatory signaling. It acts as an E3 ligase ligand and is utilized in the synthesis of PROTACERαDegrader-1.

Potent oral XIAP/cIAP1 inhibitor with EC50s: XIAP 5.1 nM, cIAP1 0.32 nM; curbs tumor growth in vivo.